Suppr超能文献

促甲状腺素分泌型垂体瘤。

Thyrotropin-secreting pituitary tumors.

作者信息

Smallridge R C

机构信息

Uniformed Services University of the Health Sciences, Bethesda, Maryland.

出版信息

Endocrinol Metab Clin North Am. 1987 Sep;16(3):765-92.

PMID:3319602
Abstract

TSH tumors are associated with both hypothyroid and hyperthyroid states. The proposed mechanism of thyrotroph secretion is illustrated in Figure 8. Pituitary enlargement in hypothyroidism is usually due to reactive hyperplasia and correlates with the degree of TSH elevation. Although this often translates to long-standing hypothyroidism and severe symptoms, this is not always the case. Patients may be asymptomatic or present with other endocrine syndromes. Children may have precocious puberty, and adults may have amenorrhea or decreased libido. One important message to remember is that whenever a patient has evidence of a pituitary tumor, a serum T4 and TSH level must be obtained. The dramatic reduction in pituitary size and resolution of endocrine dysfunction with thyroid hormone is gratifying. Thyrotropinomas producing thyrotoxicosis are autonomous tumors. Given their infrequent occurrence, one could question the cost effectiveness of ordering a serum TSH on all new patients with hyperthyroidism. Features that might favor the possibility of there being a tumor include male sex, headaches, visual impairment, and the absence of ophthalmopathy. Unfortunately, these are not reliable clinical features to suggest the presence of this disorder, and the diagnosis requires a serum TSH determination. Fortunately, the newer assays available are able to provide the sensitivity needed. Therapy should be aimed at the pituitary gland, but currently it is less than optimal. Surgery with or without external irradiation offers the best prognosis and, hopefully, will yield better results when cases are identified earlier. Medical therapy to suppress TSH is still in its infancy. More effective agents will hopefully be discovered in the near future.

摘要

促甲状腺激素(TSH)瘤与甲状腺功能减退和甲状腺功能亢进状态均有关。促甲状腺激素细胞分泌的推测机制见图8。甲状腺功能减退时垂体增大通常是由于反应性增生,且与TSH升高程度相关。虽然这通常意味着长期甲状腺功能减退和严重症状,但情况并非总是如此。患者可能无症状或伴有其他内分泌综合征。儿童可能出现性早熟,成人可能出现闭经或性欲减退。需要记住的一个重要信息是,每当患者有垂体瘤证据时,必须检测血清T4和TSH水平。甲状腺激素治疗后垂体大小显著缩小及内分泌功能障碍缓解令人满意。导致甲状腺毒症的促甲状腺激素瘤是自主性肿瘤。鉴于其发病率低,有人可能会质疑对所有新发甲状腺功能亢进患者检测血清TSH的成本效益。可能提示存在肿瘤的特征包括男性、头痛、视力障碍及无眼病。不幸的是,这些并非提示该疾病存在的可靠临床特征,诊断需要测定血清TSH。幸运的是,现有的更新检测方法能够提供所需的敏感性。治疗应针对垂体,但目前尚不理想。手术联合或不联合外照射预后最佳,且如果能更早确诊,有望取得更好的结果。抑制TSH的药物治疗仍处于起步阶段。有望在不久的将来发现更有效的药物。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验